Direct Medical Expenses and Influencing Factors of MDR/RR-TB in Eastern China: Based on Data from Multi-Hospital Information Systems

References

• World Health Organization. The end TB strategy 2015; 2015. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19. Accessed September 7, 2023.
   Google Scholar
• Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645–662. PMID: 31315696. doi:10.5588/ijtld.18.0622.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2022; 2022. Available from: https://www.who.int/publications/i/item/9789240061729. Accessed September 7, 2023.
   Google Scholar
• Yang L, Wenhong Z. Evolution of drugs and new advances in the treatment of multidrug-resistant tuberculosis. Adv Pharm. 2021;45(06):419–426.
   Google Scholar
• World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis, Guidelines for drug-resistant tuberculosis; 1997.
   Google Scholar
• Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med. 2012;9(8):e1001300. PMID: 22952439. doi:10.1371/journal.pmed.1001300
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO.Treatment guidelines for drug-resistant tuberculosis.Geneva:World Health Organization; 2016. Available from: https://www.who.int/publications/i/item/9789241549639. Accessed September 7, 2023.
   Google Scholar
• World Health Organization. Treatment guidelines for drug-resistant tuberculosis; 2018. Available from: https://www.who.int/publications/i/item/9789241550079. Accessed September 7, 2023.
   Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment; 2020 Available from: https://www.who.int/publications/i/item/9789240007048. Accessed September 7, 2023.
   Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment; 2022. Available from: https://www.who.int/publications/i/item/9789240063129. Accessed September 7, 2023.
   Google Scholar
• Prevention CCfDCa. Chinese technical guidelines for tuberculosis control and prevention 2021; 2021 Available from: https://tb.chinacdc.cn/xxjlg/202111/W020211119672904030470.pdf. Accessed September 7, 2023.
   Google Scholar
• Park H-Y, Ku H-M, Sohn H-S, et al. Cost-effectiveness of Bedaquiline for the treatment of multidrug-resistant tuberculosis in the Republic of Korea. Clin Ther. 2016;38(3):655–667. doi:10.1016/j.clinthera.2016.01.023.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2016; 2016. Available from: https://www.who.int/publications/i/item/9789241565394. Accessed September 7, 2023.
   Google Scholar
• Feuth T, Patovirta RL, Grierson S, et al. Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines. Int J Tuberc Lung Dis. 2021;25(7):554–559. PMID: 34183100; PMCID: PMCPMC8259121. doi:10.5588/ijtld.20.0892.
   PubMed Web of Science ®Google Scholar
• Wang Y, McNeil EB, Huang Z, et al. Household financial burden among multidrug-resistant tuberculosis patients in Guizhou province, China: a cross-sectional study. Medicine. 2020;99:28.
   Web of Science ®Google Scholar
• The L. China through the lens of health in 2018 and beyond. Lancet. 2018;391(10125):999. doi:10.1016/S0140-6736(18)30563-4.
   PubMed Web of Science ®Google Scholar
• Zhang G. Analysis of the Economic Burden of Multidrug-Resistant Tuberculosis in Guangzhou and the Influencing Factors. Guangdong University of Pharmaceutical Sciences; 2021.
   Google Scholar
• Jiali Y, Huizhong W, Xia Z, et al. Analysis of factors influencing the economic burden of 162 patients with multidrug-resistant tuberculosis. J Trop Med. 2020;20(04):441–445.
   Google Scholar
• Kamara RF, Saunders MJ, Sahr F, et al. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study. Lancet Glob Health. 2022;10(4):e543–e54. PMID: 35303463; PMCID: PMCPMC8938764. doi:10.1016/s2214-109x(22)00004-3
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu C-H, Wang X-M, et al. Out-of-pocket payments and economic consequences from tuberculosis care in eastern China: income inequality. Infect Dis Poverty. 2020;9(1):14. doi:10.1186/s40249-020-0623-8.
   PubMed Web of Science ®Google Scholar
• Exchange SAoF. Table of conversion rates of various currencies to the U.S. dollar; 2018. Available from: https://www.safe.gov.cn/safe/2018/0131/8255.html. Accessed September 7, 2023.
   Google Scholar
• Zhao L, Guolong Z, Yulong G, et al. Research and policy recommendations on the current situation of supply security of second-line anti-tuberculosis drugs in 5 provinces and cities. Pharmacoeconomics. 2021;16(02):121–124.
   Google Scholar
• Xingxing L, Xun L, Jianjun Y, et al. Investigation and analysis of the economic burden of pulmonary tuberculosis patients in two different economic regions of Hubei Province. Chi J Prev Med. 2016;50(1):1–6. doi:10.3760/cma.j.issn.0253-9624.2016.01.001
   PubMedGoogle Scholar
• Ruan YZ, Li RZ, Wang XX, et al. The affordability for patients of a new universal MDR-TB coverage model in China. Int J Tuberc Lung Dis. 2016;20(5):638–644. PMID: 27084818. doi:10.5588/ijtld.15.0413.
   PubMed Web of Science ®Google Scholar
• Diel R, Sotgiu G, Andres S, Hillemann D, Maurer FP. Cost of multidrug resistant tuberculosis in Germany—An update. Int J Infect Dis. 2021;103:102–109. doi:10.1016/j.ijid.2020.10.084.
   PubMed Web of Science ®Google Scholar
• Guangchuan Z. Analysis of the Economic Burden of Multidrug-Resistant Tuberculosis in Guangzhou and the Factors Affecting It. Guangdong University of Pharmaceutical Sciences; 2021.
   Google Scholar
• Li R. A Comparative Study on the Effectiveness of Prevention and Treatment Before and After the Conclusion of MDR-TB Control Project of Shandong Global Fund. Shandong University; 2019.
   Google Scholar
• Wei T, Feng W. Impact analysis of the payment reform of “same disease with the same price in the same level of hospital” diagnosis-related group based on L City, Guizhou Province: an empirical study. Lancet. 2019;394:S63. doi:10.1016/S0140-6736(19)32399-2.
   PubMed Web of Science ®Google Scholar
• Mok J, Lee M, Kim DK, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label Phase 2/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522–1530. PMID: 36522208. doi:10.1016/s0140-6736(22)01883-9
   PubMed Web of Science ®Google Scholar